Serum Ratio of Free Triiodothyronine to Thyroid-Stimulating Hormone: A Novel Index for Distinguishing Graves' Disease From Autoimmune Thyroiditis

被引:1
|
作者
Wu, Zhiyong [1 ,2 ]
Zhu, Yu [1 ,2 ]
Zhang, Min [1 ,2 ]
Wang, Chen [1 ,2 ]
Zhou, Lingli [1 ,2 ]
Liu, Wei [1 ,2 ]
Yang, Wenjia [1 ,2 ]
Li, Meng [1 ,2 ]
Zhang, Simin [1 ,2 ]
Ren, Qian [1 ,2 ]
Han, Xueyao [1 ,2 ]
Ji, Linong [1 ,2 ]
机构
[1] Peking Univ, Diabet Ctr, Peoples Hosp, Dept Endocrinol, Beijing, Peoples R China
[2] Peking Univ, Diabet Ctr, Peoples Hosp, Dept Metab, Beijing, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2021年 / 11卷
关键词
Graves' disease; autoimmune thyroiditis; thyrotoxicosis; thyroid function test; differential diagnosis; DIFFERENTIAL-DIAGNOSIS; RECEPTOR ANTIBODIES; CLINICAL-FEATURES; AUTOMATED-ASSAY; HYPERTHYROIDISM; THYROTOXICOSIS; TSH; DESTRUCTION; IMMUNOASSAY; THYROXINE;
D O I
10.3389/fendo.2020.620407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Graves' disease (GD) and autoimmune thyroiditis (AIT) are two major causes of thyrotoxicosis that require correct diagnosis to plan appropriate treatment. The objectives of this study were to evaluate the usefulness of thyroid-related parameters for distinguishing GD from AIT and identify a novel index for differential diagnosis of thyrotoxicosis. Design: This retrospective study was performed using electronic medical records in Peking University People's Hospital (Beijing, China). Methods: In total, 650 patients with GD and 155 patients with AIT from December 2015 to October 2019 were included in cohort 1. Furthermore, 133 patients with GD and 14 patients with AIT from December 2019 to August 2020 were included in cohort 2 for validation of the novel index identified in cohort 1. All patients were of Chinese ethnicity and were newly diagnosed with either GD or AIT. Thyroid-related clinical information was collected before intervention by reviewing the patients' electronic medical records. Receiver operating characteristic curve analysis was used to identify the optimal cutoff for distinguishing GD from AIT. Results: In cohort 1, thyroid-stimulating hormone (TSH) receptor antibody was identified as the best indicator for distinguishing GD from AIT. The area under the receiver operating characteristic curve was 0.99(95% confidence interval: 0.98-0.99, p<0.0001)and the optimal cutoff was 0.84 IU/l (98% sensitivity and 99% specificity). The free triiodothyronine (FT3)/TSH ratio (FT3/TSH) was the second -best for distinguishing GD from AIT, the area under the receiver operating characteristic curve of FT3/TSH was 0.86 (95% confidence interval: 0.84-0.88, p<0.0001); its optimal cutoff was 1.99 pmol/mIU (79% sensitivity and 80% specificity). Its effectiveness was confirmed in cohort 2 (81% sensitivity and 100% specificity). Conclusions: The FT3/TSH ratio is a new useful index for differential diagnosis of thyrotoxicosis, especially when combined with TRAb.
引用
收藏
页数:7
相关论文
共 40 条
  • [1] Eosinophil/Monocyte Ratio Combined With Serum Thyroid Hormone for Distinguishing Graves' Disease and Subacute Thyroiditis
    Hu, Yongbin
    Zhou, Diyi
    Chen, Jiawei
    Shan, Pengfei
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [2] Differentiating Graves' disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine
    Sriphrapradang, Chutintorn
    Bhasipol, Adikan
    ANNALS OF MEDICINE AND SURGERY, 2016, 10 : 69 - 72
  • [3] Triiodothyronine/Free Thyroxine Ratio as a Criterion for the Differentiation Between Graves' Disease and Subacute Thyroiditis
    Alidrisi, Haider A.
    Thamer, Nawar K.
    Radhi, Maher A.
    Hammadi, Saad
    Abdulaziz, Farah S.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [4] Ratio of serum free triiodothyronine to free thyroxine in Graves' hyperthyroidism and thyrotoxicosis caused by painless thyroiditis
    Noh, JY
    Momotani, N
    Fukada, S
    Ito, K
    Miyauchi, A
    Amino, N
    ENDOCRINE JOURNAL, 2005, 52 (05) : 537 - 542
  • [5] Thyroid-Stimulating Antibody/Thyroid-Stimulating Hormone Receptor Antibody Ratio as a Sensitive Screening Test for Active Graves' Orbitopathy
    Nakano, Masayoshi
    Konishi, Hiroe
    Koshiba, Masahiro
    ENDOCRINE PRACTICE, 2022, 28 (10) : 1050 - 1054
  • [6] Similar Clinical Performance of a Novel Chimeric Thyroid-Stimulating Hormone Receptor Bioassay and an Automated Thyroid-Stimulating Hormone Receptor Binding Assay in Graves' Disease
    Kamijo, Keiichi
    Murayama, Hiroshi
    Uzu, Takahiro
    Togashi, Kazuyoshi
    Olivo, Paul D.
    Kahaly, George J.
    THYROID, 2011, 21 (12) : 1295 - 1299
  • [7] Elevated Graves' Disease-Specific Thyroid-Stimulating Immunoglobulin and Thyroid Stimulating Hormone Receptor Antibody in a Patient With Subacute Thyroiditis
    Mathew, Anu Alvin
    Papaly, Roshin
    Maliakal, Alvin
    Chandra, Lakshya
    Antony, Mc Anto
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [8] Thyroid-stimulating hormone receptor and its role in Graves' disease
    Chistiakov, DA
    MOLECULAR GENETICS AND METABOLISM, 2003, 80 (04) : 377 - 388
  • [9] Genetics of Thyroid-Stimulating Hormone Receptor - Relevance for Autoimmune Thyroid Disease
    Stefan, Mihaela
    Faustino, Larissa C.
    FRONTIERS IN ENDOCRINOLOGY, 2017, 8
  • [10] Graves Disease in Children: Thyroid-Stimulating Hormone Receptor Antibodies as Remission Markers
    Gastaldi, Roberto
    Poggi, Elena
    Mussa, Alessandro
    Weber, Giovanna
    Vigone, Maria Cristina
    Salerno, Mariacarolina
    Delvecchio, Maurizio
    Peroni, Elena
    Pistorio, Angela
    Corrias, Andrea
    JOURNAL OF PEDIATRICS, 2014, 164 (05): : 1189 - +